Revance completes patient enrollment in phase 2 program for RT002 injectable
Revance Therapeutics announced it has completed enrollment of patients in the Company's Phase 2 program investigating the use of DaxibotulinumtoxinA for Injection (RT002) for management of plantar fasciitis. The study enrolled 59 subjects across five centers in the U.S. October 18, 2017